Among people with Graves disease who have been treated with medication and have normal thyroid hormone levels, those with high levels of thyroid-stimulating antibodies when stopping treatment are much more likely to experience a return of hyperthyroidism within two years than those with low or undetectable levels of these antibodies.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review and meta-analysis of prospective cohort studies using standardized TSAb assays could determine the pooled sensitivity, specificity, and predictive value of TSAb at drug withdrawal across diverse populations to establish its clinical utility.
A systematic review and meta-analysis of all prospective cohort studies measuring TSAb at antithyroid drug withdrawal in adults with newly diagnosed Graves disease, using the Mc4 assay with a cutoff of ≥140% SRR, reporting relapse over ≥18 months, with adjustment for age, sex, goiter, and treatment duration. Studies must report sensitivity, specificity, PPV, NPV, and hazard ratios with 95% CIs.
An RCT could determine whether using TSAb results to guide treatment decisions (e.g., recommending RAI for TSAb-positive patients) reduces relapse rates compared to standard care.
A multicenter, double-blind RCT of 400 adults aged 18–55 with newly diagnosed Graves disease in sustained euthyroidism after 18–24 months of antithyroid drugs, randomized to either TSAb-guided management (RAI offered if TSAb ≥140% SRR) or standard management (no TSAb testing). Primary outcome: relapse-free survival at 24 months, with secondary outcomes including cost, patient satisfaction, and adverse events.
A prospective cohort study could confirm the predictive accuracy of TSAb at drug withdrawal in a new, diverse population with standardized follow-up and blinded outcome assessment.
A prospective cohort study of 200 adults with Graves disease achieving euthyroidism after antithyroid drugs, measuring TSAb (Mc4 assay, cutoff ≥140% SRR) at drug withdrawal, then following them every 3 months for 24 months with thyroid function tests and blinded to TSAb status. Primary outcome: relapse defined as fT4 >24.45 pmol/L and TSH <0.3 mIU/L.
A case-control study could compare TSAb levels at withdrawal between patients who relapsed and those who remained in remission, controlling for known confounders to assess whether TSAb is a stronger predictor than other biomarkers.
A case-control study of 100 patients with Graves disease who relapsed within 24 months of drug withdrawal and 100 matched controls who remained in remission, comparing TSAb levels at withdrawal, adjusting for age, sex, goiter size, treatment duration, and baseline fT4. TSAb measured using Mc4 assay with blinded lab analysis.
A cross-sectional study could estimate the prevalence of TSAb positivity at drug withdrawal in a general population of Graves disease patients, but cannot assess its predictive value over time.
A cross-sectional study measuring TSAb levels at the time of antithyroid drug withdrawal in 500 consecutive adults with Graves disease across multiple centers, reporting the proportion testing positive and correlating it with baseline clinical features.